Semiannual Securities Report — FY2026 H1
What Shionogi & Co.,Ltd. reported for the period from 2026-04-01 to 2027-03-31.
Filed 2026-11-11View the original on EDINET
How much it says
59Typical
What moved here
26named for the first time
Its own wording
35terms
Which filing this is
38/ 38newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, in addition to succeeding to the edaravone business from Tanabe Pharma in April 2026, the Group finalized the provisional accounting treatments for the business combinations involving 鳥居薬品, JT’s pharmaceutical business and Akros carried out in the previous consolidated fiscal year. It also entered into a technology introduction agreement with Apnimed covering an intellectual property license for sleep-disorder assets, and the filing describes as a subsequent event that Shionogi Inc. in the United States entered into an agreement to acquire IntraBio Inc. on 5 October 2026.
Komori's summary of this document, not the document's own words.59Typical
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 38 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
68
Detailed
93
Very detailed
75
Very detailed
40
Thin
12
Almost nothing
71
Detailed
48
Typical
53
Typical
55
Typical
50
Typical
R&D spend674億円Money spent making new things.
Cash left over-2,921億円Cash from the business, less what went into equipment.
Spent on equipment73億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.